Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents.

Literature DB >> 10471590

Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents.

C Betriu¹, M Gómez, M L Palau, A Sánchez, J J Picazo.

Abstract

The antimicrobial activities of trovafloxacin, moxifloxacin, sanfetrinem, quinupristin-dalfopristin, and 14 other antimicrobial agents against 218 Bacteroides fragilis group strains were determined. A group of 10 imipenem-resistant strains were also tested. Imipenem, meropenem, and sanfetrinem had the lowest MICs of all of the beta-lactams. Quinupristin-dalfopristin inhibited all of the strains at 2 microg/ml. Overall, the MICs of trovafloxacin and moxifloxacin for 90% of the strains tested were 1 and 2 microg/ml, respectively.

Entities: Chemical Species

Mesh：

Substances：

Year: 1999 PMID： 10471590 PMCID： PMC89472

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

17 in total

1. Antimicrobial resistance in anaerobic bacteria: current situation.

Authors: J A García-Rodríguez; J E García-Sánchez; J L Muñoz-Bellido
Journal: Anaerobe Date: 1995-04 Impact factor: 3.331

2. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria.

Authors: A P MacGowan; K E Bowker; H A Holt; M Wootton; D S Reeves
Journal: J Antimicrob Chemother Date: 1997-10 Impact factor: 5.790

3. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes.

Authors: K E Aldridge; D S Ashcraft
Journal: Antimicrob Agents Chemother Date: 1997-03 Impact factor: 5.191

4. Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams.

Authors: G S Babini; M Yuan; D M Livermore
Journal: Antimicrob Agents Chemother Date: 1998-05 Impact factor: 5.191

5. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.

Authors: H M Wexler; E Molitoris; D Molitoris; S M Finegold
Journal: Antimicrob Agents Chemother Date: 1996-09 Impact factor: 5.191

6. In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.

Authors: D B Hoellman; S K Spangler; M R Jacobs; P C Appelbaum
Journal: Antimicrob Agents Chemother Date: 1998-03 Impact factor: 5.191

7. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.

Authors: D R Snydman; L McDermott; G J Cuchural; D W Hecht; P B Iannini; L J Harrell; S G Jenkins; J P O'Keefe; C L Pierson; J D Rihs; V L Yu; S M Finegold; S L Gorbach
Journal: Clin Infect Dis Date: 1996-12 Impact factor: 9.079

8. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.

Authors: K E Aldridge; M Gelfand; L B Reller; L W Ayers; C L Pierson; F Schoenknecht; R C Tilton; J Wilkins; A Henderberg; D D Schiro
Journal: Diagn Microbiol Infect Dis Date: 1994-04 Impact factor: 2.803

Review 9. Resistance of anaerobic bacteria to antimicrobial agents in Spain.

Authors: F Baquero; M Reig
Journal: Eur J Clin Microbiol Infect Dis Date: 1992-11 Impact factor: 3.267

10. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.

Authors: C Edlund; S Sabouri; C E Nord
Journal: Eur J Clin Microbiol Infect Dis Date: 1998-03 Impact factor: 3.267

10 in total

1. In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinolone.

Authors: Kaori Tanaka; Hiroshige Mikamo; Ken'ichi Nakao; Kunitomo Watanabe
Journal: Antimicrob Agents Chemother Date: 2006-11 Impact factor: 5.191

Review 2. A critical review of the fluoroquinolones: focus on respiratory infections.

Authors: George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal: Drugs Date: 2002 Impact factor: 9.546

3. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.

Authors: K E Aldridge; D Ashcraft; K Cambre; C L Pierson; S G Jenkins; J E Rosenblatt
Journal: Antimicrob Agents Chemother Date: 2001-04 Impact factor: 5.191

Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents.

1. Antimicrobial resistance in anaerobic bacteria: current situation.

2. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria.

3. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes.

4. Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams.

5. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.

6. In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.

7. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.

8. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.

Review 9. Resistance of anaerobic bacteria to antimicrobial agents in Spain.

10. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.

1. In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinolone.

Review 2. A critical review of the fluoroquinolones: focus on respiratory infections.

3. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.

Review 4. Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents.

5. In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains.

6. Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.

7. In vitro activities of newer quinolones against bacteroides group organisms.

8. In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.

9. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.

10. Moxifloxacin in the treatment of skin and skin structure infections.